VJHemOnc is committed to improving our service to you

Measuring MRD in CLL

VJHemOnc is committed to improving our service to you

William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical implications of measuring minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL). Dr Wierda outlines how MRD is useful in a practical setting as well as within clinical trial design and monitoring as a measure of progression-free survival and overall survival. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).


Warning: count(): Parameter must be an array or an object that implements Countable in /home/vjhemonc/public_html/wp-content/themes/vj/single.php on line 248
Share this video  
10th September 2020

Warning: Invalid argument supplied for foreach() in /home/vjhemonc/public_html/wp-content/themes/vj/single.php on line 443

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter